TUCSON, Ariz.--(BUSINESS WIRE)--Jan. 6, 2005--CryoFluor Therapeutics, a medical device company developing a novel cryosurgical technology platform, has received a second investment that will allow the company to complete a feasibility clinical trial of its device to treat abnormal uterine bleeding. Research Corporation Technologies (RCT), Endocare Inc. and Temple University participated in the investment.
